Salbutamol for Congenital Myopathy

What did the salbutamol trial find in children with congenital myopathy?

The COMPIS trial compared salbutamol added to usual care with usual care alone. Participants were randomly assigned to a treatment sequence and later switched groups, with a washout interval between periods. This crossover approach allowed researchers to compare each child's performance across both conditions. The study tested an oral medicine alongside existing care. [COMPIS trial registration](https://clinicaltrials.gov/study/NCT05099107).

The adjusted difference on the Motor Function Measure-32 was 3.61 points in favor of salbutamol. The researchers considered this greater than previously reported thresholds for meaningful change in congenital-onset neuromuscular disorders. Nevertheless, it represents an average difference on a functional scale, not a percentage increase in strength or a guarantee that every child improved. [Published COMPIS findings](https://doi.org/10.1016/j.eclinm.2026.104186).

The university also reported an approximately 1.5-kilogram advantage in dominant-hand grip strength compared with usual care. Findings in other muscle groups were not statistically significant, emphasizing that the evidence was stronger for some outcomes than others. [University of Gothenburg research announcement](https://www.gu.se/en/news/asthma-medication-improved-motor-skills-and-strength-in-children-with-muscle-disease).

Why might an asthma medicine help inherited muscle weakness?

Congenital myopathies are inherited disorders that can make walking, standing and using the arms difficult; some also weaken breathing muscles. Treatment generally centers on supportive care and preventing complications. Even modest functional improvements could therefore matter in everyday activities, although the practical benefit will differ between children. [University of Gothenburg disease background](https://www.gu.se/en/news/asthma-medication-improved-motor-skills-and-strength-in-children-with-muscle-disease).

The COMPIS investigators proposed that salbutamol might encourage muscle protein production and reduce protein breakdown. Its precise effects in these disorders remain uncertain. This is a drug-repurposing approach: investigating whether an established medicine can help a different condition. The hypothesis concerns supporting muscle function; it does not establish repair of the genetic cause. [COMPIS scientific rationale](https://clinicaltrials.gov/study/NCT05099107).

What limits the evidence, and what side effects matter?

COMPIS was conducted at one center, and participants knew whether they were receiving treatment, although endpoint assessment was blinded. These features limit confidence about how broadly the findings apply. No serious adverse events occurred, but five participants reported palpitations and one reported tremor. A small study cannot reliably exclude uncommon harms or establish whether benefits persist over years. [COMPIS study design and safety findings](https://doi.org/10.1016/j.eclinm.2026.104186).

Salbutamol is also called albuterol. Oral albuterol labeling warns about rapid heartbeat, blood-pressure changes and low potassium, which can affect heart rhythm. Existing heart conditions and interacting medicines can influence treatment decisions. Families considering this research should discuss it with their child's neuromuscular specialist; the findings do not support independently adding tablets or increasing an asthma inhaler. [DailyMed oral albuterol prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87b8cd3c-2849-4b50-b63e-9ea379165c07).